In summary, the present study described a novel orally active dual CysLT1R antagonist/GPBAR1 agonist that effectively protects against the development of NAFLD/NASH, showing promise for further development. Here, GPBAR1 is linked to metabolic dysfunction-associated steatohepatitis.